Hélène BOUCHER PILLET

Pharmacien hospitalier spécialisée en médicament de thérapie innovante (MTI), j'ai une expérience de 15 ans en thérapie cellulaire. Les postes de Responsable Assurance Qualité puis Responsable du laboratoire de Contrôle Qualité au sein d'une structure GMP autorisée m'ont permis d'acquérir des connaissances solides dans la fabrication de MTI expérimentaux.

• Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of life. Sitbon et al. Stem Cell Res Ther. 2024. 
• Effects of intravascular administration of mesenchymal stromal cells derived from Wharton's Jelly of the umbilical cord on systemic immunomodulation and neuroinflammation after traumatic brain injury (TRAUMACELL): study protocol for a multicentre randomised controlled trial. Sigaut et al. BMJ Open. 2024.
• Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Monsel et al. Crit Care. 2022.
• Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases. Mebarki et al. Stem Cell Res Ther. 2021. 
• Associated factors of umbilical cord blood collection quality. Faivre et al. Transfusion. 2018.
• Circadian Clock Genes Modulate Human Bone Marrow Mesenchymal Stem Cell Differentiation, Migration and Cell Cycle. Boucher et al. PLoS One. 2016.